Acetazolamide — Mechanism of Action and Carbonic Anhydrase

Acetazolamide (trade names Diamox internationally, Diuramid in Poland) is the most frequently used drug for prevention and treatment of acute mountain sickness. Its mechanism of action extends far beyond “AMS treatment” — it has been used for over 70 years in glaucoma, epilepsy, metabolic alkalosis, and idiopathic intracranial hypertension. Understanding exactly how it works allows sensible dosing, predicting side effects, and separating myths from facts.

Acetazolamide in a nutshell — three-sentence mechanism

• Carbonic anhydrase inhibitor — blocks the enzyme that metabolizes carbon dioxide in kidneys, eyes, brain, and erythrocytes.
• In kidneys: increased excretion of bicarbonate and water → metabolic acidosis.
• Acidosis stimulates the respiratory center in the brainstem → deeper breathing → higher oxygen saturation and faster acclimatization.

What is carbonic anhydrase?

Carbonic anhydrase (CA) is a family of enzymes catalyzing the reversible reaction:

CO₂ + H₂O ⇌ H₂CO₃ ⇌ H⁺ + HCO₃⁻

Without this enzyme the reaction would proceed too slowly for efficient CO₂ transport from tissues to lungs. Humans express at least 15 CA isoforms. The most relevant for acetazolamide pharmacology:

• CA II — in erythrocytes, renal tubules, ciliary body epithelium of the eye, central nervous system
• CA IV — in renal tubules (brush border) and pulmonary vessels
• CA XII — in ciliary body epithelium

Acetazolamide inhibits primarily CA II and CA IV — and this selectivity explains most of its clinical effects.

Mechanism in mountain medicine — step by step

1. Carbonic anhydrase blockade in kidneys

In the proximal and distal renal tubules carbonic anhydrase drives reabsorption of bicarbonate (HCO₃⁻) — approximately 85% of the filtrate. Acetazolamide blocks this process. Effect: increased urinary loss of bicarbonate, accompanied by sodium and water (hence the diuretic effect).

2. Metabolic acidosis — controlled and desirable

Loss of HCO₃⁻ in urine shifts blood toward acidity (pH drops from 7.40 to 7.32–7.36). This is mild metabolic acidosis, clinically insignificant in healthy individuals — but sufficient to stimulate chemoreceptors in the medulla oblongata that monitor pH and CO₂ pressure.

3. Compensatory hyperventilation

Chemoreceptors detect lower pH and signal the respiratory center: breathe faster and deeper to exhale more CO₂ and restore acid-base balance. Results:

• Minute ventilation rises by 10–30%
• More oxygen reaches alveoli → higher blood saturation
• Higher saturation = less tissue hypoxia = reduced AMS risk

At altitude the body physiologically hyperventilates but often “not enough”. Acetazolamide is in practice a pharmacological forcing of this compensation — the body reacts as if already acclimatized, though physiologically still adjusting. Hence the shortened adaptation time.

4. Additional beneficial effects

• Reduced respiratory alkalosis — physiological altitude hyperventilation causes respiratory alkalosis that paradoxically limits further ventilation increase. Acetazolamide “releases this brake”.
• Improved sleep breathing stability — at altitude Cheyne-Stokes breathing (alternating apneas and hyperventilation) fragments sleep and worsens nocturnal hypoxia. Acetazolamide reduces frequency and depth of these episodes.
• Moderate diuretic effect — useful in mild peripheral edema, but at altitude watch hydration carefully.

Other indications — beyond mountain medicine

• Glaucoma — reduces aqueous humor production by ciliary body epithelium (CA II and XII), lowering intraocular pressure. Dose 250 mg 2–4×/day.
• Epilepsy — stabilizes neuronal membranes (CA blockade in CNS limits depolarization). Used in petit mal in children and grand mal in adults. Shows efficacy in catamenial epilepsy (cyclic regimen).
• Metabolic alkalosis — e.g. after prolonged mechanical ventilation or loop diuretic use.
• Idiopathic intracranial hypertension (pseudotumor cerebri) — reduces cerebrospinal fluid production.
• Drug- or cardiac-induced edema (rare indication today, replaced by newer diuretics).

AMS use is off-label in many countries, but Wilderness Medical Society Guidelines 2019 and European UIAA MedCom and ICAR MedCom consensuses clearly recommend acetazolamide in AMS prophylaxis and early treatment.

Pharmacokinetics — practical essentials

• Absorption: rapid, complete; plasma peak after ~2 h
• Distribution: good blood-brain and placental barrier penetration
• Protein binding: ~90% — relevant for interactions with albumin-bound drugs
• Metabolism: virtually none — not metabolized in liver, excreted mostly unchanged
• Excretion: 70–100% in urine within 24 h
• Half-life: 4–8 h
• Steady state: reached after ~48 h of regular dosing — hence the recommendation to start 24 h before planned altitude exposure

The drug is safe in hepatic insufficiency (no hepatic metabolism) but requires caution in severe renal insufficiency (GFR <30 mL/min) — accumulation and amplified side effects.

Side effects — mechanism and minimization

Paresthesias (tingling in fingers and around the mouth)

Occur in 60–90% of patients taking acetazolamide. Mechanism: mild metabolic acidosis + decreased CO₂ alter calcium and potassium ion exchange in sensory neuron membranes. Paresthesias are usually mild, symptoms intensify during exertion (hyperventilation). Not dangerous — they indicate the drug is working.

Diuresis and frequent urination

Direct effect of blocked HCO₃⁻ reabsorption in kidneys. Increase fluid intake by 1–2 L/day during acetazolamide use. Take the evening dose early (6–7 PM), not right before sleep — avoid nocturnal toilet trips in cold conditions.

Taste disturbances

Classic harmless side effect: carbonated drinks taste “metallic” or “stale”. Mechanism: acetazolamide blocks CA in taste bud cells responsible for sour taste and “fizziness” perception. Cola, beer, mineral water have a very specific taste on acetazolamide — nothing to do but wait for drug withdrawal.

Rare serious side effects

• Sulfonamide-type allergic reactions — acetazolamide contains a sulfonamide group. Cross-reactivity risk in patients allergic to sulfonamides (e.g. trimethoprim/sulfamethoxazole, sulfasalazine): rash, angioedema, rarely Stevens-Johnson syndrome. Contraindication.
• Agranulocytosis — granulocyte count <0.5 G/L. Frequency <0.01%. Symptoms: high fever, sore throat, severe general condition.
• Kidney stones — with long-term use (months). Minor issue in mountain medicine (1–3 weeks), relevant in glaucoma or IIH treatment.
• Hypokalemia — at doses above 750 mg/day and use >2 weeks consider potassium supplementation (20 mmol/day).

Contraindications

• Sulfonamide allergy — absolute
• Severe renal insufficiency (GFR <30 mL/min) — absolute
• Severe hepatic insufficiency with cirrhosis — acetazolamide worsens tubular alkalosis, risk of hepatic encephalopathy
• Uncorrected hypokalemia
• Addison’s disease
• Hyperchloremic acidosis
• First trimester of pregnancy — relative; teratogenicity data mixed

Drug interactions

• Aspirin (high doses) — acetazolamide metabolic acidosis + salicylism = risk of severe acidosis and salicylate toxicity. Avoid combination.
• Lithium — acetazolamide increases lithium clearance, may reduce therapeutic levels.
• Digoxin — induced hypokalemia may amplify digoxin toxicity.
• Metformin — increased risk of lactic acidosis (theoretical, clinically rare).
• Oral contraceptives — no significant interaction, safe.

Why “drugs like candy” is a bad idea

I am not a big fan of “just-in-case” pharmacological prophylaxis. In the climbing community there is a tendency to take acetazolamide “for safety” before every expedition above 3000 m — regardless of ascent pace, predispositions, or medical history. In my opinion this is an error for several reasons:

• Natural acclimatization is a physiological process with more durable effects (on subsequent expeditions the body “remembers” parts of the mechanism).
• Side effects are real — paresthesias, diuresis-related insomnia, taste changes are not a comfort worth paying for in a healthy person with time to acclimatize.
• False sense of security — some climbers ignore AMS symptoms “because they’re on Diamox”. The drug reduces risk but does not eliminate it.
• Cost and logistics — prescription drug, requires consultation, unnecessarily complicates preparation for those without indications.

Acetazolamide prophylaxis makes sense in people with HAPE/HACE history, logistics-forced rapid ascent (e.g. flying to Cusco at 3700 m), or inability to maintain the 300–500 m rule. For the rest — gradual ascent, hydration, rest day after each 1000 m, and symptom monitoring.

Specific prophylactic and therapeutic dosing in a dedicated article: Diamox (acetazolamide) — prophylactic and therapeutic dosing.

Frequently asked questions

References

• Luks AM, Auerbach PS, Freer L, et al. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019 Update. Wilderness Environ Med. 2019;30(4S):S3–S18.
• Leaf DE, Goldfarb DS. Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. J Appl Physiol. 2007;102(4):1313–1322.
• Basnyat B, Gertsch JH, Johnson EW, et al. Efficacy of low-dose acetazolamide (125 mg BID) for prophylaxis of acute mountain sickness: RCT. High Alt Med Biol. 2003;4(1):45–52.
• Ward, Milledge & West’s High Altitude Medicine and Physiology, 6th ed. CRC Press, 2021.

Medical notice: Acetazolamide (Diuramid/Diamox) is a prescription drug. Do not use without consulting an expedition or travel medicine physician. This article is educational and does not replace individual health assessment. On expeditions, in emergencies call 112, TOPR 601 100 300, GOPR 985 (Poland) or your local rescue service.